Physician profile
Vincent J Bobby
NPI 1811962780
$5,246.05
in general payments reported to CMS, 2019-2025
25 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $260 · 2021: $310 · 2022: $453 · 2023: $791 · 2024: $1,237 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,782.15 | 2022-2025 | |
| Vifor Pharma, INC. | $1,467.60 | 2019-2025 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.14 | 2023-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $296.11 | 2019-2021 | |
| Akebia Therapeutics INC | $243.87 | 2024-2025 | Vafseo, Auryxia |
| Medtronic, INC. | $171.23 | 2025 | Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $146.86 | 2019-2024 | Farxiga |
| Pulmonx Corporation | $122.98 | 2023-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Ardelyx, INC. | $81.61 | 2024 | Ibsrela |
| Lilly USA, LLC | $77.19 | 2023-2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $69.71 | 2020-2021 | |
| Calliditas Therapeutics US INC. | $60.22 | 2022-2023 | Tarpeyo |
| Fresenius USA Marketing, INC. | $52.31 | 2023-2025 | Velphoro, Velphoro |
| Alexion Pharmaceuticals, INC. | $47.89 | 2019 | |
| Novo Nordisk INC | $46.48 | 2025 | Rybelsus, Ozempic, Wegovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $38.35 | 2023 | |
| Amgen INC. | $36.60 | 2022-2024 | Repatha |
| Covidien LP | $33.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.65 | 2025 | |
| Pfizer INC. | $27.36 | 2024 | |
| Mallinckrodt Enterprises LLC | $20.86 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.43 | 2024 | Jynarque |
| Glaxosmithkline, LLC. | $19.09 | 2023 | Benlysta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Bobby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.